Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 14
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
PROCEPT BioRobotics Corp
PRCT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$19.10
-0.47
-2.4%
Ult. Agg.: Oct 13, 4:00 PM
$19.76
0.19
0.97%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
PROCEPT BioRobotics Financials
PROCEPT BioRobotics (PRCT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $397.424M Est
PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $397.424 million estimate.
Benzinga Newsdesk
PRO
PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate
PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent. This is a 34.29 percent decrease over losses of $(0.35) per share
Benzinga Newsdesk
PRO
PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $396.674M Est
PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $396.674 million estimate.
Benzinga Newsdesk
PRO
PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate
PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.56) per share which met the analyst consensus estimate. This is a 24.44 percent decrease over losses of $(0.45) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why
PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million.
Vandana Singh
